Did you know?

ChinaBio® Group is a consulting and advisory firm helping life science companies and investors achieve success in China. ChinaBio works with U.S., European and APAC companies and investors seeking partnerships, acquisitions, novel technologies and funding in China.  

Learn more >>

Free Newsletter

Have the latest stories on China's life science industry delivered to your inbox daily or weekly - free!

  Email address:

CanSino to Add Shanghai Star Board IPO to Hong Kong Listing

publication date: Oct 14, 2019

CanSino Biologics, a Tianjin vaccine company, filed to IPO on the Shanghai Star Board, six months after it completed a $161 million initial offering in Hong Kong. In the first day of trading following the Hong Kong IPO, CanSino rose 58%, and it remains 72% above the IPO price six months later. The company said it would issue 24.8 million shares in the Shanghai offering, but it has not set its pricing goals yet. CanSino has an approved Ebola vaccine and six vaccine candidates in clinical trials or CTA stage, along with 6 pre-clinical vaccine candidates. More details....

Stock Symbol: (HK: 6185)

Share this with colleagues:

This article is available for purchase - please click here for details.

Sorry this page is available to subscribers only.
If you're not a subscriber why not subscribe today?

If you are already a subscriber, please login.

If you believe you should have received this message in error, please contact us.


To gain access to the members only content click here to subscribe.

You will be given immediate access to premium content on the site.

ChinaBio® News

Greg Scott BIO-Europe Interview
Greg Scott Interviewed at BIO-Europe Spring

How to bring your China assets to China in 8 minutes

Greg Scott Mendelspod Interview
"Mr. Bio in China."
Mendelspod Interview

Multinational pharma held to a higher standard in China